Cognition Therapeutics Q1 net loss $8.5M; cash $16.4M; requests EOP2 for Alzheimer's

COGNITION THERAPEUTICS INC

2025-Q1 EPS reported -$0.14

Net loss of $8.5M ($0.14 per share) compared to $9.2M ($0.27) in Q1 2024.
Cash and equivalents $16.4M plus $47M in NIH grants; runway into Q4 2025.
Requested End-of-Phase 2 meeting with FDA to discuss Alzheimer's SHINE study and registrational trial.
Phase 2 SHIMMER study in dementia with Lewy bodies accepted for oral presentation at AAIC July 2025.
Presenting two posters at ARVO on zervimesine's role in regulating lipid metabolism and retinal cell protection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.